We’re pleased to announce the completion of enrollment in Precision-T, the pivotal Phase 3 study of our lead investigational allogeneic T-cell immunotherapy, Orca-T. To learn more: https://bit.ly/3X7Og2E #bloodcancer #AML #oncology #leukemia #celltherapy
Orca Bio’s Post
More Relevant Posts
-
Deep dive into training pertaining to clinical trial investigation for fellows by Ardaman Shergill - Anand Patel American Society of Clinical Oncology (ASCO) Ajay Major, MD, MBA The University of Chicago Section of Hematology/Oncology https://lnkd.in/dv52zkHv #ASCO24 #Cancer #CancerResearch #Leukemia #MedicalConference #OncoDaily #Oncology
To view or add a comment, sign in
-
📰by The Journal of Clinical Oncology, this international multicenter retrospective study of patients with RT who received CAR-T concluded that CAR-T demonstrates clinical efficacy for patients with RT. READ➡️https://lnkd.in/eN_8Civm #bloodcancer #hematology #oncology #cancer #leukemia #hematologyoncology
To view or add a comment, sign in
-
We’re looking forward to presenting positive data supporting the clinical profile of our investigational high-precision cell therapy, Orca-T, at the 50th Annual Meeting of The EBMT. To learn more: https://bit.ly/3TWWhEw #EBMT24 #bloodcancer #AML #oncology #leukemia
To view or add a comment, sign in
-
While immune checkpoint inhibitors have incredible results for certain metastatic cancers, the majority of patients don’t respond or suffer irAEs. Download our guide to improving the efficacy and safety of ICIs: https://lnkd.in/eSXNhTeB #ICIs #Oncology
To view or add a comment, sign in
-
Platinum is known to be the most effective therapy available for ovarian cancer patients, however most patients will eventually stop responding to treatment. Platinum resistance definition by Gynecologic Oncology Group (GOG): Platinum sensitivity is classified as refractory, resistant, partially sensitive or sensitive, according to the time elapsed since finishing first-line treatment. Genelux is working to provide options for those who no longer respond to platinum-based treatment. Our phase 2 trial showed clinical reversal of platinum resistance or refractoriness. Read more about our previous trials at https://loom.ly/qt5Pg4o #Stage4NeedsMore #OvarianCancer #CancerResearch
To view or add a comment, sign in
-
This week’s practice-changing study looks at the extended follow-up of the phase 3, randomized, open-label CLEAR study which evaluated lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment in advanced renal cell carcinoma. Patients who had not received any systemic anticancer therapy were eligible and were randomly assigned to receive either the combination of lenvatinib and pembrolizumab, or sunitinib. The primary endpoint was progression-free survival. Results from the extended follow-up confirm that lenvatinib plus pembrolizumab provides durable and clinically meaningful benefits over sunitinib, thus supporting its use as a first-line therapy for patients with advanced renal cell carcinoma. This study was selected by Dr. Richard Cathomas, one of the Oncology Compass Scientific Leaders, and can be found on our website: https://lnkd.in/dUADmZp2 #cancerresearch #oncology #oncologyresearch
To view or add a comment, sign in
-
FDA approved #pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent #endometrialcarcinoma. Evidence was from the KEYNOTE 868 Trial #Cancer #PrecisionMedicine #Immunotherapy #Oncology #NewApproval 🔗 https://lnkd.in/gsAMPNS6
To view or add a comment, sign in
-
🔑 Is Adjuvant Immunotherapy the key to better Melanoma treatment? Join Dr. Jason Luke this week as he discusses the latest in adjuvant immunotherapy for Stage IIB/C melanoma. Learn how to integrate these treatment options into your practice and effectively manage immune-related adverse events in early-stage patients. 🔗Only a few sessions left- register now: https://ow.ly/Gtw950R2gzu #Melanoma #FOAMed #Webinar #melanomaawareness #Immunotherapy #Oncology #MedLearningGroup
To view or add a comment, sign in
-
We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC - Paolo Tarantino #Cancer #DanaFarberCancerInstitute #Govitecan #HER2 #OncoDaily #Oncology
To view or add a comment, sign in
-
Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive Advanced/Metastatic NSCLC 📢 #MedicalOncology #CancerNews #Oncology #Cancer
Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive Advanced/Metastatic NSCLC
esmo.org
To view or add a comment, sign in
13,328 followers